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Abstract
Objective: PAX6 is a pleiotropic transcription factor essential for the develop-
ment of several tissues including the eyes, central nervous system, and some
endocrine glands. Recently it has also been shown to be important for the
maintenance and functioning of corneal and pancreatic tissues in adults. We
hypothesized that PAX6 is important for the maintenance of brain integrity in
humans, and that adult heterozygotes may have abnormalities of cortical pat-
terning analogous to those found in mouse models. Methods: We used
advanced magnetic resonance imaging techniques, including surface-based mor-
phometry and region-of-interest analysis in adult humans heterozygously
mutated for PAX6 mutations (n = 19 subjects and n = 21 controls). Using
immunohistochemistry, we also studied PAX6 expression in the adult brain tis-
sue of healthy subjects (n = 4) and patients with epilepsy (n = 42), some of
whom had focal injuries due to intracranial electrode track placement (n = 17).
Results: There were significant reductions in frontoparietal cortical area after
correcting for age and intracranial volume. A greater decline in thickness of the
frontoparietal cortex with age, in subjects with PAX6 mutations compared to
controls, correlated with age-corrected, accelerated decline in working memory.
These results also demonstrate genotypic effects: those subjects with the most
severe genotypes have the most widespread differences compared with controls.
We also demonstrated significant increases in PAX6-expressing cells in response
to acute injury in the adult human brain. Interpretation: These findings suggest
a role for PAX6 in the maintenance and consequent functioning of the adult
brain, homologous to that found in other tissues. This has significant implica-
tions for the understanding and treatment of neurodegenerative diseases.
Introduction
PAX6 is a highly conserved transcription factor essential
to the development of several tissues including the eyes,
brain, and endocrine glands of vertebrates and inverte-
brates.1 In the mouse, Pax6 is critical for survival: Pax6
null mice die immediately after birth with absent eyes
and nasal structures, and with a diencephalon that fails to
innervate a severely malformed cerebral cortex.2 Analysis
of Small eye mouse embryos carrying homozygous Pax6
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loss-of-function mutations has demonstrated the critical
role of Pax6 in the dorsoventral specification and cortical
arealization of telencephalic brain regions, and its impor-
tance in cortical progenitor proliferation, and axonal
migration within the brain.3 Only a few cases of children
with mutations in both PAX6 alleles (compound
heterozygotes) have been reported, and severe eye and
brain abnormalities similar to those reported in homozy-
gote mice were found in these patients.4 In contrast to
homozygote models, heterozygote mice have not been
widely studied. In addition to the Small eye ocular
anomalies,5 the olfactory bulbs of heterozygote mice are
reduced in size.6 Heterozygous PAX6 mutation in humans
is known to cause aniridia7 and hyposmia or anosmia.8
Such parallels between human and rodent developmental
anomalies suggest that aniridia presents a unique oppor-
tunity to study the multiple roles of PAX6 in humans.
Previous magnetic resonance imaging (MRI) studies in
an aniridia cohort showed unsuspected consequences of
heterozygous PAX6 mutation, including absence of the
anterior commissure without callosal agenesis, absence or
reduction in the olfactory bulb and the pineal gland,
polymicrogyria, and an altered configuration of midline
anatomy.8–10 In addition, functional studies revealed defi-
cits in working memory,11 olfaction,8 and central auditory
function.12 These observations imply developmental
hypoplasia or subsequent pathological degeneration or
both: the distinction is important. Recent animal studies
have suggested an important role for Pax6 in the mainte-
nance and functioning, as well as development, of cor-
neal,13,14 and pancreatic tissues.15 A parallel role for PAX6
in the maintenance of brain integrity in humans has
major implications for our understanding of neurodegen-
erative disorders, and their potential treatment with stem
cell-based therapies. Furthermore, the opportunity to
study structural and functional details in human cases is
critical, given that the details of developmental pathways
may differ in humans and mice.16
In this study, we hypothesized that PAX6 is important
for the maintenance of brain integrity in humans, and
that adult heterozygotes may have abnormalities of corti-
cal patterning analogous to those found in mouse models.
We investigated novel cerebral MRI parameters in 19
adults with known PAX6 mutations (Table 1), using
whole brain surface-based morphometry (SBM), and
lobe-based region-of-interest (ROI) analysis. Additionally,
PAX6 expression was studied by immunohistochemistry
in resected adult brain tissue. SBM is an unbiased, whole-
brain approach that, unlike voxel-based morphometry
(VBM), prevents the conflation of cortical area and thick-
ness changes.17 Advanced quantitative postprocessing
techniques provide an opportunity to extract more infor-
mation from imaging data, which is important given the
rarity of this condition, and the difficulty in obtaining
pathological data in such a small, selected group.
Materials and Methods
Subjects
Nineteen people with aniridia (aged 18–73 years, 10 men)
were recruited through their attendance at a tertiary cen-
ter for eye disease. Subjects have been pheno- and geno-
typically described previously8–11 but underwent further
clinical, imaging, and neuropsychology assessments as
part of this study. Twenty-two normal control subjects
(aged 23–62 years, 11 men) were also studied for compar-
ison. These subjects had no reported neurological or psy-
chiatric abnormalities. The research ethics committees of
the Institute of Neurology, National Hospital for Neurol-
ogy and Neurosurgery, and Moorfields Eye Hospital,
approved the study protocols. All subjects provided writ-
ten informed consent.
MR data acquisition
Magnetic resonance imaging studies were performed on a
3T GE Excite II scanner (General Electric, Wakashua, Mil-
waukee, WI). Standard imaging gradients with a maximum
strength of 40 m/Tm and slew rate 150 Tm/s were used. All
data were acquired using a body coil for transmission, and
eight-channel phased array coil for reception. The scanning
protocol also included a coronal T1-weighted volumetric
acquisition sequence with 1.1-mm thick slices. No parallel
acquisition techniques were used.
MR image processing
MR images were transferred in DICOM format to a dedi-
cated Linux workstation (Centos 5). Cortical reconstruc-
tion and volumetric segmentation were performed using
surface-based morphometry (SBM) with the Freesurfer
v5.1 image analysis suite (http://surfer.nmr.mgh.
harvard.edu/). The technical details of SBM are described
and referenced on the Freesurfer website (http://surfer.
nmr.mgh.harvard.edu/). Processing includes several stages:
removal of non-brain tissue using a hybrid watershed/
surface deformation procedure, automated Talairach
transformation, segmentation of the subcortical white
matter, deep gray and white matter volumetric structures,
intensity normalization, tessellation of the gray and white
matter boundaries, automated topology correction, and
finally surface deformation using intensity gradients to
place the gray/white and gray/cerebrospinal fluid (CSF)
borders optimally at the location where the greatest shift
in intensity defines the transition to the other tissue class.
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In this process, voxels are classified as white matter or
something other than white matter based on intensity
and neighbor constraints. An initial surface is then gener-
ated for each hemisphere by tiling the outside of the
white matter mass for that hemisphere. This initial sur-
face is then refined to follow the intensity gradients
between the white and gray matter (this is referred to as
the white surface). The white surface is then nudged to
follow the intensity gradients between the gray matter
and CSF (this is the pial surface). The distance between
the white and the pial surfaces equates to the thickness at
each location of the cortex. Surface models of the cortical
surface are generated, consisting of a mesh of triangles,
and the location of the mesh is controlled by adjusting
the location of the vertices. A vertex is the place where
the points of neighboring triangles meet and are typically
about 1 mm apart. The vertex positions are adjusted such
that the surface follows the contour of the maximum T1
intensity gradient between cortical white matter (WM),
and cortical gray matter (GM), and between the cortical
gray matter and pia. All surfaces are constructed in native
anatomical space.
Following completion of the cortical models, a number
of deformation procedures were performed in further
data processing and analysis. These included surface infla-
tion allowing both sulcal and gyral folds to be visualized,
registration of each vertex on the inflated surface to a
spherical atlas which utilized individual cortical folding
patterns to match cortical geometry across subjects, par-
cellation of the cerebral cortex into six subject-specific
lobar regions per hemisphere based on gyral and sulcal
structure, and the creation of surface-based data including
maps of cortical volume, thickness, and area. The spheri-
cal atlas naturally forms a coordinate system in which
point-to-point correspondence between subjects can be
achieved. Mean vertex-wise thickness, area and volume
Table 1. Demographic and genetic information on PAX6 subjects.
Subject
No.
Age/
gender
Mutation at
DNA level
Exon (protein
domain) Protein prediction Mutation type
1 40/F c.115_116dupCC 5 (PD) p.Cys40ArgfsX15 PTC by frameshift in PD predicted - NMD likely
2 18/F c.683-6T>A 9 (HD) p.Glu228GlyfsX5 PTC by frameshift. Exon 9 skipped (RT-PCR). NMD likely
3 41/F c.718C>T 9 (HD) p.Arg240X PTC by direct stop codon mutation – NMD likely
4 61/M c.763C>T 9 (HD) p.Gln255X PTC ultimately. Mutation in last codon of exon 9 may create stop
codon and/or affect splicing leading to frame shift. NMD likely
5 40/M c.763C>T 9 (HD) p.Gln255X PTC ultimately. Mutation in last codon of exon 9 may create stop
codon and/or affect splicing leading to frame shift. NMD likely
6 33/M c.775dupT 10 (HD) p.Ser259PhefsX2 PTC resulting from predicted frameshift. NMD likely
7 36/M c.775dupT 10 (HD) p.Ser259PhefsX2 PTC resulting from predicted frameshift. NMD likely
8 43/M c.357 + 2dupT 6 (PD) 36 aa deletion In-frame deletion of 36 aa predicted in PD by RT-PCR following
splice site mutation and activation of weak exonic splice site
9 38/M c.357 + 5G>A 6 (PD) 36 aa deletion In-frame deletion of 36 aa likely predicted in PD following probably
splice site mutation and activation of weak exonic splice site
10 41/F DNA mutation
unknown
6 (PD) 36 aa deletion In-frame deletion of 36 aa predicted in PD by RT-PCR following
activation of weak exonic splice site. Actual mutation not found –
may be deep intronic change
11 35/M del exon 10 + 11 10, 11 (PST) 88 aa deletion In-frame deletion of 88 aa predicted as a result of deletion of exons
10 and 11 identified by MLPA
12 60/F c.1239delT 13 (PST) p.Asp413GlufsX*46 C-terminal extension predicted as a result of frame-shift beyond the
NMD boundary
13 49/M c.1267dupT 13 (PST) p.X423LeuextX*108 C-terminal extension predicted as a result of single-nucleotide
insertion abolishing stop codon
14 52/M c.1267dupT 13 (PST) p.X423LeuextX*108 C-terminal extension predicted as a result of single-nucleotide
insertion abolishing stop codon
15 50/F c.1267dupT 13 (PST) p.X423LeuextX*108 C-terminal extension predicted as a result of single-nucleotide
insertion abolishing stop codon
16 37/M c.1267dupT 13 (PST) p.X423LeuextX*108 C-terminal extension predicted as a result of single-nucleotide
insertion abolishing stop codon
17 37/F c.191G>T 6 (PD) p.Gly64Val Missense change predicted in PD
18 73/F c.191G>T 6 (PD) p.Gly64Val Missense change predicted in PD
19 25/F c.372C>A 6 (PD) p.Asn124Lys Missense change predicted in PD
PTC, premature termination codon; NMD, nonsense-mediated decay (destruction of mRNA by cellular protection mechanism against protein frag-
ment interference); PD, paired domain; HD, homeo domain; PST, proline serine threonine-rich transactivation domain; aa, amino acid.
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differences between groups can then be displayed on the
pial surface of the standard atlas. All cortical surface maps
were smoothed with a 10 mm full-width at half-maxi-
mum surface-based Gaussian kernel to reduce local varia-
tions in the measurements for further analysis.
Vertex-wise analysis
Cortical thickness
Representations of cortical thickness are produced using
both intensity and continuity information from the entire
three-dimensional MR volume in the segmentation and
deformation procedures. Thickness is calculated as the clos-
est distance from the gray/white boundary to the gray/pial
boundary at each vertex on the tessellated surface. The
maps are created using spatial intensity gradients across tis-
sue classes and are therefore not simply reliant on absolute
signal intensity. The maps produced are not restricted to
the voxel resolution of the original data and thus are cap-
able of detecting submillimeter differences between groups
as validated by histologic studies.18
Cortical surface area
The area assigned to each vertex on the tessellated cortical
pial surface was calculated as the average area of all trian-
gles of which the vertex is a member. The surface area of
a region can be computed by adding up the area of the
vertices in that region. To compare patients to controls
and obtain maps of surface area alterations, we applied
previously described methods.19 The deformation and
registration of individual spheres into the common coor-
dinate system result in a standard number of tessellations
across each individual’s cortical surface. However, the
surface area values assigned to each vertex are redis-
tributed to reflect the relative expansion and contraction
of the cortical sheet around each vertex. This provides
point-by-point estimates of the relative areal expansion or
compression of each vertex across the entire cortical man-
tle in atlas space, and enables group-wise quantification
of cortical surface area.
Intracranial volume
An estimate of intracranial volume (ICV) was provided
by FreeSurfer based on the transformation of each sub-
ject’s brain into Talairach space.
Statistical analysis
We analyzed differences in cortical pial area and thickness
by computing a general linear model (GLM) of the effect
of patient-control status or group on each measure across
the entire cortex at each vertex as implemented in the
Query Design Estimate Contrast (QDEC) interface of
FreeSurfer. Age and ICV were included as covariates in
the analysis as both have been shown to correlate with
thickness and surface area in both whole brain and ROI
studies.20 We also checked for interactions between the
covariates and group with regard to each dependent
measure. Unless otherwise indicated, there was no inter-
action between group and each covariate on dependent
measures.
Statistical parametric maps of significant group differ-
ences or group-covariate interaction, were corrected for
multiple comparisons using Monte Carlo simulation
methods using a vertex-wise (cluster-forming threshold)
and clusterwise threshold of P < 0.05. The P-value for a
cluster was determined through simulation in which
white Gaussian noise was repeatedly synthesized on the
surface, spatially smoothed, thresholded, and clustered to
determine the distribution of cluster sizes under the null
hypothesis. Correlation analysis of back-normalized clus-
ters of interest and neuropsychology scores was assessed
using a Spearman correlation test because the neuropsy-
chology data were not normally distributed.
Cortical ROI analysis
All cortical ROI analyses were carried out using IBM
SPSS Statistics for Macintosh, Version 18.0 (IBM Corp.,
Armonk, NY). The normality of continuous variables was
assessed using the Shapiro–Wilk and Kolmogorov–Smir-
nov tests. The Student’s t-test (parametric distribution)
was used to compare group differences in ICV, while the
Wald–Wolfowitz runs omnibus test (nonparametric dis-
tribution) was used to compare both the location of the
mean and the distribution of age within each group. The
Wald–Wolfowitz runs test compares distribution locations
and shapes for two groups by combining the two groups
and ranking the data. Group differences in the distribu-
tion of the sexes were assessed using the chi-squared test.
A mixed design multivariate analysis of covariance
(MANCOVA) was performed to investigate cortical lobar
area/thickness differences between groups. In all ROI
analyses, preliminary checks were conducted in order to
ensure that there was no violation of the assumptions of
univariate and multivariate normality, homogeneity of
variances, and homogeneity of regression slopes. Where
appropriate, statistical thresholds had a Bonferroni correc-
tion applied.
The dependent variables used in the cortical ROI analy-
sis were the mean lobar area/thickness. The regions con-
sidered were the frontal, cingulum, occipital, temporal,
parietal, and insula lobes, based on the Desikan–Killiany
atlas as implemented in Freesurfer. The between-subjects
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independent variable was patient-control status or
group, and the within-subjects independent variable was
hemisphere (right or left). The latter was used to exclude
any group-by-side interaction. The covariates age and
ICV were also included in the analysis. Hemisphere had
no significant effect on cortical area or thickness, and
unless otherwise indicated there was no significant inter-
action between hemisphere and group, nor between group
and each covariate on dependent variables. Correlations
between cortical thickness and age were assessed using
Pearson’s correlation test. All correlations are reported
using two-tailed P-values.
Neuropsychology assessment
Neuropsychological tests measured aspects of cognition
associated with brain regions identified as abnormal or
implicated in previous studies; they are listed below. Due
to the visual deficits that are common in this patient
group, only verbal measures were used.
Intellectual level
The vocabulary, digit span, and similarities tests from the
Wechsler Adult Intelligence Scale–Revised were adminis-
tered, and the scores were prorated to obtain an estimate
of the participant’s verbal intellectual capacity.
Executive functions
Subjects completed fluency measures requiring firstly the
reciting of as many words beginning with the letter S
(phonemic fluency) in 1 min and then as many animal
names (semantic fluency) also in 1 min. The Hayling
Test, a response suppression task, was administered. This
requires the subject to complete two series of 15 sen-
tences, each of which is missing the last word.21 In the
first series, a sensible completion is required and in the
second a nonsensical completion. Performance is mea-
sured in terms of mental processing speed and accuracy.
Memory
A prose recall task was used to assess immediate and
delayed verbal recall. A verbal learning task was used to
assess the ability to learn and retain a list of fifteen words
over five trials. Both measures were taken from the Adult
Memory and Information Processing Battery.22
We expected a high degree of correlation between flu-
ency scores (semantic and phonemic fluency), and
between episodic memory scores (story recall, delayed
story recall, list learning, delayed list learning). Therefore,
we used a principal components analysis within SPSS
v18.0 to identify a factor accounting for the largest com-
ponent of variance among each of these two sets of
scores. By reducing these scores to a single verbal fluency
score, and a single episodic memory score we were able
to reduce the number of statistical correlation analyses
carried out.
Histopathologic studies
The final part of this study used immunostaining in adult
human neocortex to demonstrate PAX6 expression in
both nonepilepsy controls (n = 4) and epilepsy surgical
tissues [with gliosis only (n = 5), focal cortical dysplasia
(FCD) IA (n = 3), FCDIIB (n = 5), FCDIIIA (n = 6),
FCDIIIB (n = 6), FCD IIID (n = 4), and cases with
intracranial recording electrode track injuries (n = 17)].
Sections from formalin-fixed paraffin-embedded tissue
blocks, cut at 5 lm, were double-labeled with combina-
tions of antibodies against PAX6 (1:100; Santa Cruz
Biotechnology, Inc., Dallas, TX) and either GFAP (glial
fibrillary acidic protein, 1:1500; Dako, Cambridge, UK),
nestin (1:6000; Millipore, Watford, UK), calretinin (1:300,
Swant, Switzerland), beta-tubulin (1:700 Sigma Aldrich,
Dorset, UK), or doublecortin (1:350, Abcam, Cambridge,
UK) using conventional immunohistochemical tech-
niques. Specimens with FCD were classified using the
ILAE classification system.23 Single- and double-labeled
cells were quantified in defined regions-of-interest (e.g.,
around electrode tracts or along cortical layer I/II) using
Image Pro Plus (Media Cybernetics, Inc., Rockville, MD).
These regions were selected as sites involved with acute or
chronic gliosis. The densities of PAX6-labeled cells were
compared between groups using the Kruskal–Wallis test
using SPSS v18.0.
Results
Subject demographics and properties
Table 1 outlines the characteristics of the subjects with
PAX6 mutations. Mutations identified in the study group
fall into four previously defined categories24: (1) intra-
genic mutations leading to predicted premature protein
termination, which is likely to lead to nonsense-mediated
decay so that no protein is produced from the mutant
allele (n = 7); (2) splice site mutants or exon deletions
leading to a predicted in-frame deletion of 36 or 88
amino acids in the paired or PST-rich transactivation
domains, respectively (n = 4); (3) mutations causing pre-
dicted C-terminal protein extension that would produce
an abnormally elongated protein (n = 5); and (4) paired-
domain missense mutations (n = 3). Subjects and con-
trols had a median age of 40 years (range 18–73 years)
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and 32 years (range 23–62 years), respectively. A
comparison of the combined location of the mean, and
distribution of the ages within both groups, revealed no
significant overall difference. There was no significant dif-
ference in the mean ICV or sex distribution between
groups.
Whole-brain analysis
Using SBM-based methods and correcting for age and
ICV, there were clusters of significantly reduced cortical
area in PAX6 subjects in the calcarine cortex, precentral
and rostral frontal areas, and the superior parietal lobe in
both hemispheres (Fig. 1; Table 2). There was a signifi-
cant interaction between group and age on cortical thick-
ness, with a steeper decline in cortical thickness with age
in PAX6 subjects than in controls. The most significant
clusters were found in the inferior parietal, prefrontal,
and precentral areas in both hemispheres (Fig. 2;
Table 3). The cortical regions of these clusters are consid-
ered as the important substrate not only for working
memory25 but also episodic memory.26 There was a bor-
derline positive correlation between age-corrected digit
span and mean cortical thickness across all significant
clusters in the left hemisphere (rs = 0.542, P = 0.030; cor-
rected alpha 0.025, two-tailed), and a significant correla-
Figure 1. Results of whole-brain group analysis comparing cortical area in PAX6 subjects and controls including age and intracranial volume as
covariates of no interest. Highlighted regions represent significant reductions in cortical area in PAX6 subjects compared to controls, and were
seen in the calcarine cortex, and parts of the frontal and parietal lobes in both hemispheres. All results are corrected for family wise errors. The
P-values of the clusters shown extend from 0.0001 (light blue) to 0.02 (dark blue), and are superimposed on lateral/medial views of the left/right
inflated hemispheres derived from the Freesurfer FsAverage brain template made in MNI305 space. Coordinates and P-values for clusters are
documented in Table 2.
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tion in the right hemisphere (rs = 0.574, P = 0.020; cor-
rected alpha 0.025, two-tailed). In order to assess the
specificity of this correlation, we also carried out a post
hoc analysis of the relationship between the thickness of
these clusters and verbal fluency and episodic memory.
There were positive correlations between episodic mem-
ory and mean cortical thickness across all significant clus-
ters in the left (rs = 0.715, P = 0.002; 2-tailed) and right
hemispheres (rs = 0.732, P = 0.002; 2-tailed). There were
no significant correlations between cortical thickness and
fluency. There was no significant difference in cortical
thickness between the groups.
We carried out two further whole-brain analyses, and an
ROI analysis to corroborate these results. First, we repeated
the analysis excluding controls under the age of 30 (n = 13
remaining) to eliminate group differences in mean age. The
results were comparable, with the number and locations of
significant clusters being similar to those described above
(Tables S1 and S2). Second, we divided PAX6 subjects into
two subgroups. Those with premature protein truncation
or C-terminal extensions tend to have the most severe ocu-
lar phenotypes compared to other mutations.24 The whole-
brain analysis of area was repeated using these “severe” and
“mild” subgroups. Compared to controls using a Bonfer-
roni-corrected alpha threshold of 0.025, the mild subgroup
had less widespread and less significant reductions in
whole-brain cortical area (Fig. 3; Table 4), than the more
severe subgroup (Fig. 4; Table 5).
Region-of-interest analysis
We also carried out an ROI analysis using atlas-defined
lobar regions (Table 6). After adjusting for age and ICV,
there was a significant effect of group [F(6,32) = 4.992,
P = 0.001, Wilks’ k = 0.517, partial g2 = 0.483] on corti-
cal area. PAX6 subjects had significantly smaller frontal
[F(1,37) = 9.397, P = 0.004, partial h = 0.203], parietal
[F(1,37) = 19.623, P < 0.001, partial h = 0.347], cingulate
[F(1,37) = 13.391, P = 0.001, partial h = 0.266], and
occipital lobar areas [F(1,37) = 15.664, P < 0.001, partial
h = 0.297], but not insular [F(1,37) = 0.584, P = 0.450,
partial h = 0.016] or temporal lobar [F(1,37) = 5.408,
P = 0.026, partial h = 0.128] areas (corrected alpha
0.008). The PAX6 mild-severe ROI analysis corroborated
these results and demonstrated a dose-dependent effect of
PAX6: after adjusting for age and ICV more severely
affected subjects had more widespread reductions in lobar
area compared to controls [F(12,62) = 2.936, P = 0.003,
Wilks’ k = 0.407, partial g2 = 0.362] (Table 7).
There was a significant interaction between the covari-
ates age and group on cortical thickness in the ROI analysis
[F(6,30) = 2.755, P = 0.030, Wilks’ k = 0.645, partial
h = 0.355]. Using a Bonferroni-adjusted alpha of 0.008, the
group-by-age interaction was significant for the frontal lobe
[F(1,35) = 10.935, P = 0.002, partial h = 0.238], and bor-
derline significant for the parietal lobe [F(1,35) = 7.814,
P = 0.008, partial h = 0.183]. In the remaining lobes, there
was no significant age-group interaction with respect to
cortical thickness. Further analysis, using a Bonferroni-cor-
rected alpha of 0.006, revealed that age was negatively cor-
related with cortical thickness in the left/right frontal
(r = 0.792, P < 0.001/r = 0.705, P = 0.001) and pari-
etal (r = 0.634, P = 0.002/r = 0.640, P = 0.002) lobes
in PAX6 subjects, but not in the left/right frontal
(r = 0.034, P = 0.442; r = 0.052, P = 0.411) or parietal
lobes (r = 0.109, P = 0.319; r = 0.002, P = 0.497) of con-
trols (Fig. 5). The PAX6 mild-severe ROI analysis corrobo-
rated these results, and demonstrated a dose-dependent
effect of PAX6. When the results for the combined hemi-
spheric, dependent variables were considered separately
Table 2. Results of whole-brain analysis—clusters of smaller area in PAX6 subjects compared to controls while including age and intracranial
volume as covariates of no interest.
Cluster number
(hemisphere)
Surface area
size (mm2)
Talairach coordinates
maximum vertex (x, y, z)
Clusterwise
probability
Atlas location of
maximum vertex
1 (left) 3528.08 13.4, 91.2, 3.8 0.00010 Pericalcarine
2 (left) 2445.86 40.8, 11.8, 48.1 0.00010 Precentral
3 (left) 1636.25 22.1, 41.5, 24.1 0.00010 Rostral middle frontal
4 (left) 1412.04 7.8, 72.8, 46.2 0.00010 Precuneus
5 (left) 1127.17 20.6, 43.4, 61.5 0.00280 Superiorparietal
1 (right) 4736.81 14.3, 77.4, 4.8 0.01880 Pericalcarine
2 (right) 1199.94 61.5, 34.9, 14.2 0.00010 Middle temporal
3 (right) 1098.00 35.0, 82.7, 0.6 0.00360 Lateral occipital
4 (right) 1088.29 27.2, 41.2, 52.0 0.02620 Superior parietal
5 (right) 887.52 35.3, 31.9, 22.7 0.00150 Fusiform
6 (right) 849.41 23.5, 42.7, 23.3 0.00380 Rostral middle frontal
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using a Bonferroni-adjusted alpha level of 0.008 the group-
by-age interaction was borderline significant only for the
frontal lobe [F(2,32) = 5.354, P = 0.01, partial theta =
0.251] such that only severely affected subjects showed a
significant decline in cortical thickness with age compared
to controls (Fig. 6).
Table 3. Results of whole brain- analysis—clusters of greater decline in cortical thickness with age in PAX6 subjects compared to controls while
including intracranial volume as a covariate of no interest.
Cluster number
(hemisphere)
Surface area
size (mm2)
Talairach coordinates
maximum vertex (x, y, z)
Clusterwise
probability
Atlas location of
maximum vertex
1 (left) 2564.12 36.8, 18.3, 64.5 0.00010 Precentral
2 (left) 1630.18 38.1, 50.0, 3.4 0.01590 Rostral middle frontal
3 (left) 967.01 41.3, 67.3, 27.3 0.00010 Inferior parietal
1 (right) 2132.38 34.0, 71.1, 28.7 0.02300 Inferior parietal
2 (right) 1325.30 24.8, 0.1, 46.0 0.00140 Caudal middle frontal
3 (right) 956.65 46.9, 42.5, 37.6 0.00010 Supramarginal
Figure 2. Results of whole-brain group analysis comparing the correlation between age and cortical thickness in PAX6 subjects and controls.
Highlighted regions represent areas where cortical thickness declined quicker with age in PAX6 subjects than controls, that is, predominantly in the
inferior parietal lobe, and prefrontal and premotor areas in both hemispheres. All results are corrected for family wise errors. The P-values of the
clusters shown extend from 0.0001 (light blue) to 0.02 (dark blue), and are superimposed on lateral/medial views of the left/right inflated hemispheres
derived from the Freesurfer FsAverage brain template made in MNI305 space. Coordinates and P-values for clusters are documented in Table 3.
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Tissue analysis
We saw colabeling of PAX6 with GFAP and nestin and to a
lesser extent with beta-tubulin, calretinin and doublecortin,
as evidence for expression in both glial and neuronal lin-
eage cells, and in immature and differentiated cell types.
PAX6/GFAP double-labeled cells were numerous in the
superficial cortex, white matter, and deeper cortex in all
Figure 3. Results of whole-brain analysis comparing area in mildly affected PAX6 subjects versus controls, including age and intracranial volume
as covariates of no interest. Highlighted regions represent significant reductions in cortical area in PAX6 subjects compared to controls, and were
seen in the medial occipital lobe and middle temporal lobe in mildly affected PAX6 subjects compared to controls. The reduction in cortical area
when compared to controls is less extensive than that seen in severely affected PAX6 subjects (see Fig. 4). All results are corrected for family wise
errors. The P-values of the clusters shown extend from 0.0001 (light blue) to 0.03 (dark blue), and are superimposed on lateral/medial views of
the left/right inflated hemispheres derived from the Freesurfer FsAverage brain template made in MNI305 space. The coordinates and P-values of
the clusters are documented in Table 4.
Table 4. Results of whole-brain analysis—clusters of smaller area in “mildly affected” PAX6 subjects compared to controls while including age
and intracranial volume as covariates of no interest.
Cluster number
(hemisphere)
Surface area
size (mm2)
Talairach coordinates
maximum vertex (x, y, z)
Clusterwise
probability
Atlas location of
maximum vertex
1 (left) 815.43 12.9, 96.8, 14.5 0.02600 Lateral occipital
1 (right) 1117.41 62.6, 10.5, 20.4 0.00310 Middle temporal
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Figure 4. Results of whole-brain analysis comparing area in severely affected PAX6 subjects versus controls, including age and intracranial
volume as covariates of no interest. Highlighted regions represent significant reductions in cortical area in PAX6 subjects compared to controls,
and were seen in the frontal and occipital lobes in severely affected PAX6 subjects compared to controls. The reduction in cortical area when
compared to controls is more extensive than that seen in mildly affected PAX6 subjects (see Fig. 3). All results are corrected for family wise errors.
The P-values of the clusters shown extend from 0.0001 (light blue) to 0.04 (dark blue), and are superimposed on lateral/medial views of the left/
right inflated hemispheres derived from the Freesurfer FsAverage brain template made in MNI305 space. The coordinates and P-values of the
clusters are documented in Table 5.
Table 5. Results of whole-brain analysis—clusters of smaller area in “severely affected” PAX6 subjects compared to controls while including age
and intracranial volume as covariates of no interest.
Cluster number
(hemisphere)
Surface area
size (mm2)
Talairach coordinates
maximum vertex (x, y, z)
Clusterwise
probability
Atlas location of
maximum vertex
1 (left) 3382.89 13.4, 91.2, 3.8 0.00010 Pericalcarine
2 (left) 1552.61 40.8, 11.8, 48.1 0.00010 Precentral
3 (left) 866.21 30.3, 46.4, 10.8 0.01690 Rostral middle frontal
1 (right) 6784.06 14.3, 77.4, 4.8 0.00010 Pericalcarine
2 (right) 992.30 61.5, 34.9, 14.2 0.02070 Middle temporal
3 (right) 877.62 27.7, 14.4, 60.2 0.03520 Precentral
4 (right) 804.14 23.5, 42.7, 23.3 0.00810 Rostral middle frontal
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epilepsy cases (Fig. 7). The mean density in the superficial
cortex of PAX6/GFAP colabeled cells was 55.6/mm2 across
all epilepsy cases and controls with no significant difference
in densities by underlying pathology. In the gliotic cavities
adjacent to electrode track injuries, significant increases in
both PAX6/nestin (peak 68.8/mm2 in acute injuries) and
PAX6/GFAP (peak 69.8/mm2 in acute injuries) colabeled
cells were noted compared to normal gray and white matter
(1.29 and 21.9/mm2, respectively) (Fig. 7; P < 0.001).
Discussion
This is the first study is to assess cortical area, and thick-
ness in human heterozygotes with PAX6 mutations. Using
whole-brain and ROI methods, we have demonstrated
exaggerated cortical thinning with age, and abnormalities
of cortical patterning in people with heterozygous muta-
tion in PAX6. Furthermore, we have demonstrated in
patients with PAX6 mutation, a reduction in cortical
thickness that correlates with a decline in working
memory in patients, beyond that expected for age. These
observations show a genotype effect; those patients with
genotypes likely to give rise to less functional protein and
more severe ocular phenotypes, appear to have more sev-
ere cortical changes. In the second part of this study, we
have also demonstrated on-going expression of PAX6 in
adult human cortex in a range of cell types, and dynamic
change in PAX6 expression in relation to gliosis and
injury. In view of these findings, we hypothesize that
PAX6 may have a role not only in human brain develop-
ment, but also brain maintenance and resulting function.
This has significant implications for our understanding of
neurodegenerative disorders: modulation of PAX6 may
offer novel therapeutic strategies.
Cortical area
Cortical area was reduced in PAX6 patients primarily in
the frontal, parietal, cingulate, and occipital lobes. Animal
models of Pax6 support these findings. Embryonic mouse
models have demonstrated that Pax6 is expressed in a
rostrolateral to caudomedial gradient in the telen-
cephalon, and specifies particular rostral and lateral
domains such as the primary motor cortex, and
somatosensory cortex.27 Loss of Pax6 function in mice
results in marked compression of the rostral cortical areas
at the level of the motor, cingulate and sensory cortex,
accompanied by rostral shift and expansion of the caudal
or visual cortex.3 Although cortical patterning has not
been studied in heterozygous animal models, two studies
have assessed the effect of heterozygous PAX6 mutations
on cortical gray matter in humans.10,28 However, both
studies used VBM-based methods which conflate area and
cortical thickness, and used unmodulated data which
makes any data interpretation problematic.28 The reduc-
tion in frontal and parietal lobe areas seen in this study
Table 6. Region-of-interest (ROI)-based estimated combined hemi-
spheric lobar area for PAX6 patients and controls when corrected for
age and intracranial volume (ICV).
Lobe Group Mean area (mm2) SE (mm2)
Frontal* Controls 36,079 555
PAX6 33,472 600
Cingulum* Controls 3801 84
PAX6 3332 90
Occipital* Controls 11,193 234
PAX6 9771 254
Temporal Controls 19,326 339
PAX6 18,117 367
Parietal* Controls 24,804 410
PAX6 22,019 444
Insula Controls 2043 43
PAX6 1993 46
*Indicates significant difference (P < 0.008) between patients and
controls. SE, standard error.
Table 7. Region-of-interest-based estimated combined hemispheric
lobar area for “mildly affected” and “severely affected” PAX6 sub-
jects and controls when corrected for age and intracranial volume
(ICV). When the lobar areas were considered separately using planned
group contrasts, and a Bonferroni-adjusted alpha level of 0.008, the
only significant difference between mildly affected and control sub-
jects was in the parietal lobe (P = 0.001). When controls were com-
pared to severely affected subjects, parietal (P = 0.001), occipital
(P < 0.001), cingulate (P = 0.002), and frontal (P = 0.009) lobar areas
were significantly smaller.
Lobe Group Mean area (mm2) SE (mm2)
Frontal Controls 36,078 562
Mild 33,582 977
Severe* 33,408 752
Cingulum Controls 3801 85
Mild 3368 147
Severe* 3312 113
Occipital Controls 11,192 234
Mild 10,114 406
Severe* 9573 313
Temporal Controls 19,327 338
Mild 17,630 588
Severe 18,399 453
Parietal Controls 24,805 413
Mild* 21,662 718
Severe* 22,226 553
Insula Controls 2043 42
Mild 1900 72
Severe 2047 56
SE, standard error.
*Indicates significant difference between patients and controls.
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has therefore not been described before in human
heterozygotes. The finding of a reduction in cingulate
cortical area has been replicated in both homozygous
mouse studies,29 and indirectly in VBM-based studies of
human heterozygotes,28 and is consistent with an endoge-
nous rostrocaudal expression gradient. Reduced occipital
Figure 5. Results of region-of-interest analysis. Cortical thickness declines with age in both the frontal and parietal lobes in PAX6 subjects, but
not controls, over the age range sampled. Age was negatively correlated with cortical thickness in (A) the left/right frontal (r = 0.792,
P < 0.001/r = 0.705, P = 0.001) and (B) the left/right parietal (r = 0.634, P = 0.002/r = 0.640, P = 0.002) lobes in PAX6 subjects only
(Bonferroni-corrected alpha of 0.01).
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lobe area in PAX6 patients has also been previously
demonstrated indirectly by VBM studies in human
heterozygotes,10 but is likely to be confounded by the sec-
ondary effects of visual impairment in these patients.30
Age-related decline in cortical thickness
Cortical thickness declines with age at a greater rate in
PAX6 patients compared to controls in the frontal and
parietal lobes, and particularly the prefrontal, precentral,
and inferior parietal cortex. Given that these areas have
been shown to be important in working memory25 and
given previous findings reported by our group,11 we
hypothesized and confirmed that the cortical thickness of
these areas correlated with age-corrected working memory.
These areas are also important for episodic memory26 and
a post hoc analysis confirmed that thickness in these areas
correlated significantly with episodic memory function, but
not other neuropsychological variables. The lethality of the
homozygous embryonic mouse models, and paucity of
animal heterozygote studies, has resulted in limited investi-
gation into the role of Pax6 in neuronal maintenance in
adult mice. In contrast, there is an increasing body of evi-
dence suggesting that Pax6 plays an important role in the
maintenance of adult corneal and pancreatic tissue. Hart
et al. inactivated Pax6 at 6 months of age in a conditional
mouse model to assess the effect of losing Pax6 function in
adulthood.15 The effect on glucose homeostasis and the
expression of key islet cell markers was measured. Homozy-
gous Pax6 deletion mice, but not controls, presented with
symptoms of diabetes. Immunohistochemical analysis of
the pancreas revealed complete loss of Pax6 and reduced
expression of insulin, glucagon, and somatostatin. Other
markers of islet cell function were also affected. Other stud-
ies have shown that Pax6 is critical to the maintenance and
regeneration of the corneal epithelium.13 Ouyang et al.
showed that this is related to the role of PAX6 in facilitating
the maintenance and differentiation of explanted human
limbal stem cells into corneal epithelial cells.14 Indeed,
heterozygous loss of PAX6 function is also associated with
corneal surface disease in people with aniridia, in whom
corneal opacification is frequently observed as transparent
epithelial cells normally maintained by limbal stem cells are
replaced by opaque conjunctiva-like cells.31
Figure 6. Results of region-of-interest analysis showing that cortical thickness declines significantly with age in the frontal lobes in severely
affected PAX6 subjects (bottom row), but not in the mildly affected PAX6 subjects (top row). Parameter assessments and partial correlations, with
a Bonferroni-corrected alpha of 0.004, show that while controls and mildly affected PAX6 subjects had no correlation between left or right
frontal lobe thickness and age, respectively (top row), a borderline significant negative correlation was present for severely affected PAX6 subjects
(bottom row) (r = 0.857, P < 0.001 and r = 0.755, P = 0.004).
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Indirect evidence supporting a maintenance role for
PAX6 in the brain emerges from the increased prevalence
of an absent anterior commissure in adults compared to
child heterozygotes.32 It is also now increasingly appreci-
ated that gene regulatory programs launched early in fetal
life to specify neuronal-type identities, continue to
function later in life to maintain postmitotic identities.33
Indeed, animal models have demonstrated the persistence
of Pax6 expression,34 and its role in the generation of
neural stem progenitor cells35 and maintenance of neuro-
genic fate36 in the adult rodent brain. Ninkovic et al.
demonstrated that ongoing expression of Pax6 in mature
Figure 7. Results of PAX6 immunostaining study. (A) Surgical tissue from an epilepsy surgical sample of temporal lobe cortex with gliosis only.
Nuclear labeling is shown for PAX6 in reactive astrocytes in cortical layer I which are GFAP-positive; (B) Cellular colocalization was demonstrated
with confocal laser scanning microscopy (Zeiss LSM610 Meta) for PAX6 and GFAP; (C) In a surgical case of focal cortical dysplasia type IIB,
colocalization of PAX6 and nestin is observed in reactive cells (arrows, and a binucleate cell, double arrow); (inset) reactive PAX6-positive and
nestin-positive glial cells are also observed in the vicinity of an electrode track injury site with reactive gliosis. (D) Confocal imaging demonstrated
occasional colocalization between PAX6 and calretinin in the superficial cortex (arrowed cell). Scale bar corresponds to 25 lm in all images;
B–D nuclei counterstained with DAPI.
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healthy brain is intrinsically required for the survival of
dopaminergic neurons in the olfactory bulb through
maintenance of crystalline aA expression, which prevents
caspase-3-mediated programmed cell death.37 In the
absence of Pax6 function, all dopaminergic olfactory bulb
neurons in mature brain died by apoptosis. We previously
showed absent or small olfactory bulbs in people with
aniridia.8 Together, these findings show that PAX6 is
likely to have roles in maintenance of adult human brain
structures, as well as their development.
Given the importance of neural stem cells to tissue repair
and cognitive performance in aging,38,39 and the rostrocau-
dal distribution of cortical abnormalities seen in nonlethal
adult cortex-specific Pax6 knockout mice,40 it is reasonable
to suggest that heterozygous PAX6 mutation may accelerate
age-related decline because of the normal role of PAX6 in
maintaining neural stem cells and promoting neuronal dif-
ferentiation.41 The role of PAX6 in maintenance may
underlie the faster rate of age-related frontoparietal cortical
thinning seen in this study. Age-related memory decline
has been shown to be aggravated by loss of structural brain
integrity in old age,42 which may be expected to result in an
accelerated decline in working memory beyond expected
age-related changes in adult human PAX6 heterozygotes.
Supporting these findings, previous reports have high-
lighted deficits in working memory,11 and cognitive and
behavioral abnormalities related to frontal executive dys-
function in both human PAX6 heterozygotes43 and Pax6
mouse models.40 Ellison-Wright et al. reported one such
family, and demonstrated using fMRI and executive tasks,
reduced functional activation in areas similar to those
described in this study, namely prefrontal and premotor
areas.28 Our findings demonstrate a direct physical conse-
quence of reduced PAX6 function on adult human brain
structure, showing dose-dependency, and underpinning the
previous observations.
Dynamic changes in PAX6 expression in
human tissue
Postnatal animal studies have shown that there is strong
expression of Pax6 in neurons in various brain regions,
including the olfactory bulb, amygdala, thalamus, and cere-
bellum. Modest expression is seen in the subgranular zone
of the hippocampal dentate gyrus and in the ependymal
layer and the subventricular zone of the lateral ventricle,
the two areas in which neurogenesis takes place throughout
life.41 Furthermore, rat models of transient brain ischemia
have demonstrated dynamic upregulation of Pax6 expres-
sion with reactive astrogliosis, which is thought to represent
a protective response to tissue injury.44 The results reported
here directly demonstrate ongoing expression of PAX6 in
adult cortex in a range of cell types for the first time in
human subjects. Dynamic change in PAX6 expression, in
relation to gliosis and injury, was also noted, supporting a
role for PAX6 in adult human cortex in the process of glio-
genesis35 and in the maintenance of neuronal cells.34,45
Recent studies based on murine cell lines46 and large-scale
single cell RNA sequencing47 have shown that Pax6 influ-
ences the process of neurodegeneration through cascades of
genes involved in growth, differentiation, and maturation
of neurons and glia, and is an important regulatory mecha-
nism for the maintenance of adult cell-type identity.
Limitations
The mean age in the patient and control groups differed,
and this may have contributed to differences in cortical
parameters between groups. However, age was included as
a confounding variable in the analysis of group differences
in area, and given that the difference in age versus thick-
ness correlation was the primary finding of interest, it is
reassuring to note that there was no statistical difference
in the combined location of the mean, and distribution of
the ages within both groups. Furthermore, the whole-brain
analysis group results remained similar even when younger
control subjects were excluded, such that there was no sig-
nificant difference in the mean age between groups. Some
studies have argued the relationship between cortical
parameters and age may vary by location in the brain and
may not be consistently linear.48 However, the finding that
the extent of cortical differences between the groups varied
depending on the severity of the PAX6 genotype suggests
that the observed differences are due to genetic factors
rather than other variables. Indeed, animal studies have
also shown that Pax6 has dose-dependent effects.49 Fur-
thermore, it is difficult to fit nonlinear models to the data
reported here given the small number of subjects. Given
the resolution of current MRI techniques, it is also not
possible to ascertain the specific biological cause of
reduced cortical thickness, which may be due to a variety
of factors including neuronal loss, shrinkage of neurons,
reductions of synaptic spines, or lower number of
synapses.50 However, regardless of the downstream biolog-
ical mechanisms, PAX6 appears to be important for the
maintenance of brain structure, although we could not
formally evaluate the developmental effects of PAX6 muta-
tion that might have confounded some of our findings.
Conclusion
PAX6 plays a role in the modulation and progression of
cortical volume and function changes in adult life. The
importance of PAX6 for the maintenance of cortical
structures has significant implications for their function
and for neurodegenerative disorders. Modulation of PAX6
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might in turn offer novel avenues for the treatment of
neurodegenerative diseases.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Results of whole-brain analysis—clusters of
smaller area in PAX6 subjects compared to controls over
30 years of age while including age and intracranial
volume as covariates of no interest.
Table S2. Results of whole-brain analysis—clusters of
greater decline in cortical thickness with age in PAX6
subjects compared to controls over 30 years of age while
including intracranial volume as a covariate of no interest.
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 17
M. Yogarajah et al. PAX6, Brain Structure and Function in Human Adults
